9 Early-Stage Brain Health Startups to Watch

Why Brainalyze stands out

Brainalyze is tackling a specific clinical question: determining which underlying condition may be responsible for dementia symptoms. Its working MX-Raman prototype and precursor spectroscopy studies provide a technical starting point, but the studies are not a prospective validation of the proposed blood test. One precursor study reported 93% accuracy for Alzheimer's classification in a held-out set of 28 cerebrospinal-fluid samples; a separate study used post-mortem brain spectra. Those sample types and evaluation settings matter when assessing how well the approach might translate to routine blood testing.

What Brainalyze is building

The startup is developing a laser-based blood test that captures biochemical patterns rather than relying on a single disease marker. Its intended use is differentiation of dementia causes to support earlier clinical investigation and more informed treatment decisions.

Why Admentia stands out

Admentia's Marco assistant has analysed more than 2,400 consultation videos, tracked over 320 patients and extracted over 180,000 behavioural markers. Co-founder Alain Nguyen holds a doctorate focused on multimodal AI for cognitive assessment, while Max Bayle and Jonathan Arnaud previously developed Ludinnov.

What Admentia is building

Marco turns consultation recordings into editable clinical reports and structured observations of cognitive and emotional function. It is intended to help clinicians compare changes between visits while retaining responsibility for clinical interpretation.

Why Herencia stands out

Herencia focuses on risk assessment at a stage when memory symptoms may not yet be apparent. Its ETH Zurich spinout origin and work with the University of Antioquia's genetic Alzheimer's cohort are meaningful research links. The evidence is best understood as clinical-method development, rather than proof that a stand-alone eye test can diagnose Alzheimer's disease.

What Herencia is building

Herencia is developing a non-invasive approach using pupil responses and decision behaviour to identify patterns associated with Alzheimer's risk. The intended opportunities include leaner assessment settings and selection for prevention research. Performance in the appropriate populations, and how risk estimates are communicated, will be central to clinical adoption.

Why neurodAIgnostics stands out

neurodAIgnostics combines academic neuroscience, AI expertise and early technical validation to address a time-consuming part of cognitive assessment. A 2024 study of the underlying research model achieved a mean absolute scoring error of 1.13 in independent prospective validation, providing an encouraging foundation for automated cognitive-test scoring.

The University of Zurich spin-off has also secured an Innosuisse grant for work with University Hospital Zurich and CSEM, and launched a Dutch-language assessment pilot with Kenniscentrum Revalidatiegeneeskunde Utrecht. Co-founder Nicolas Langer brings neuroscience research experience from Harvard Medical School, while Arnaud Bistoquet holds a PhD in machine learning for medical imaging from Georgia Tech. Together, these signals point to a research-backed technology moving toward practical clinical use.

What neurodAIgnostics is building

neurodAIgnostics is developing AI software that converts photographs of completed paper-based cognitive tests into suggested scores and structured reports. By preserving familiar assessments while automating parts of the scoring and documentation process, the technology aims to reduce clinicians' administrative workload, improve consistency and free up more time for patient assessment.

The investment opportunity lies in making established cognitive-testing workflows more efficient without requiring clinicians to abandon the tools they already use.

Why optohive stands out

optohive belongs in a different purchasing and evidence category from clinical diagnostics. Its research-use-only HiveOne platform secured confirmed six-figure research-system orders and a distribution agreement with ANT Neuro. Those are early commercial indicators tied to scientific equipment rather than treatment or diagnosis. The system originated at ETH Zurich's Rehabilitation Engineering Lab.

What optohive is building

optohive is developing HiveOne, a wearable optical brain-imaging system that allows researchers to measure brain activity while participants move and perform tasks in more natural environments. Unlike conventional laboratory setups that restrict movement, HiveOne is designed to make brain imaging more flexible and accessible across different research settings.

The system enables neuroscience teams to investigate brain function during real-world activities and collect measurements across repeated sessions, opening new possibilities for studying cognition, behaviour and how the brain responds to different tasks and environments.

Why Cellestial Health stands out

Cellestial Health targets astrocyte communication networks rather than focusing solely on neurons. It secured £515,000 in pre-seed equity financing in May 2025, while 2025 human post-mortem tissue research found reduced connexin 43 in late-stage Parkinson's cases. A separate 2026 cell-and-rat study reported effects on inflammation and alpha-synuclein pathology; neither result establishes patient treatment efficacy.

What Cellestial Health is building

The startup develops small molecules intended to preserve astrocyte-network communication in Parkinson's disease. Its thesis is that improving the environment around vulnerable neurons could contribute to a disease-modifying treatment strategy.

Why CicaNeuro stands out

CicaNeuro has preclinical Parkinson-like animal-model evidence reporting protection of vulnerable neurons and improved motor performance. Its lead programme is supported by exclusive patent licences from the Paris Brain Institute, including rights associated with CN101.

What CicaNeuro is building

CicaNeuro is developing small-molecule medicines designed to protect neurons and slow the degeneration associated with Parkinson's disease. Unlike Cellestial Health's support-cell strategy, its programme centers on neuronal protection.

Why FloBiotech stands out

FloBiotech combines brain-cell models of neurodegeneration with small-molecule therapeutic development. Its preclinical validation, licensed intellectual property, financing and university partnership provide foundations for advancing the platform.

What FloBiotech is building

FloBiotech is developing human brain-cell models to study the mechanisms behind neurodegenerative diseases and identify new therapeutic opportunities. Its approach combines disease-relevant laboratory models with small-molecule drug development, initially targeting Alzheimer's disease and related tau disorders.

By bringing human brain biology into the drug-discovery process, FloBiotech aims to identify compounds that act on the brain's protective pathways and advance them toward treatments that address the underlying disease rather than only its symptoms.

Why Cerebrovia Therapeutics stands out

Persistent symptoms following concussion can affect day-to-day functioning long after the original injury. Cerebrovia Therapeutics is pursuing drug development for this particular patient group rather than a general neurodegenerative-disease programme. Its clinical-research and scientific-founder signals provide an early foundation for a differentiated therapeutic strategy.

What Cerebrovia Therapeutics is building

Cerebrovia Therapeutics is developing medicines for people experiencing persistent symptoms after a concussion. Its work focuses on the longer-lasting effects of brain injury, where symptoms can continue well beyond the initial recovery period and interfere with everyday activities.

The startup aims to develop treatments that address these ongoing symptoms and improve recovery and quality of life for people living with persistent post-concussion difficulties.